Woman taken to hospital after being bitten by animal at Darling Downs Zoo
It's understood the woman was bitten by a big cat.
Emergency services said they were called to the Darling Downs Zoo in Pilton, south of Toowoomba, around 8:30am this morning.
The woman was assessed at the scene and subsequently transported to Brisbane's Princess Alexandra Hospital in a stable condition.
A post on the zoo's Facebook page confirmed it would be closed all day due to "unforeseen circumstances".
Darling Downs Zoo has been contacted for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
SBS Australia
4 minutes ago
- SBS Australia
Australian early intervention program for deaf children piloted in Japan
Baby Rafael is hearing for the first time, with a cochlear implant unlocking a new world of sound. The small electronic device - which is surgically implanted - helps deaf people perceive sound. Rafael's mother, Renata Reis, says her son was six months old when he was fitted with the technology. "That's where the magic happens. There's the beautiful day that we were waiting for this first six months of his life where he could hear us for the first time. That was unbelievable. We were waiting, so excited for this day." Rafael, now 13, was diagnosed with profound hearing loss soon after birth. And so too, were his younger brothers, 10-year-old Gabriel and six-year-old Luca. The Sydney-based siblings all had the device implanted around the age of six months but it was just the beginning of their journey towards hearing and speaking. While a cochlear implant can be life-changing, the technology alone is not enough, says Dr Aleisha Davis, CEO of the Shepherd Centre, a not-for-profit that helps children with hearing loss learn to listen and speak. "There's such a misconception that hearing aids or cochlear implants help a child hear, but they don't. They provide access and the technology helps them hear sound, but brains aren't wired to understand sound at such early ages. So we provide the therapy that enables the children to understand what those signals are and to learn to use them in their everyday environments." The brothers also took part in the Shepherd Centre's early intervention program. The children are now thriving, says their mother Renata, who migrated to Australia from Brazil 17 years ago. Music is a big part of the family's cultural identity and the two eldest boys are members of their school band. "The program here was essential for them to thrive. You come here for maybe a day in the week, but it's all about the work that you put in every single day, exposing them to language, to sounds and music. They're doing quite well at school. They are very social little people." It was a decade ago that prominent Japanese hearing health specialist Doctor Akira Takagi first learnt about the work at the Shepherd Centre. He says in Japan, children diagnosed with hearing loss who wish to receive a cochlear implant don't typically have the surgery until the age of one or two. In Australia, it's around six months. "The sooner the surgery the better the outcomes." And Doctor Takagi adds there's a lack of services in Japan to teach children how to use the devices. He says he was 'amazed' by the program offered by the Shepherd Centre. "This is the system I am trying to create in Japan in collaboration with the Shepherd centre." This month that became a reality with the launch of an early intervention pilot program. Aleisha Davis says the partnership has been a decade in the making. "I am thrilled that it's happening and that we can help many more children than those locally here in Australia. It really will change the way that children grow up learning to listen with cochlear implants in Japan." Not all children born with hearing impairment use a cochlear implant. Some families opt for Auslan, while others are bilingual using both sign-language and spoken language. Shirley Liu, the CEO of Deaf Australia - the main association representing deaf people in Australia - says there is a diversity of experiences. Speaking to SBS in Auslan, which we've translated to spoken language, she emphasises the need for access to sign language from birth. "It's not an either/or, black or white, system that you can either have access to sound or access to Auslan and they can be used in conjunction with each other. Our position is that Auslan is essential and it's a valuable and vital language for deaf children to have access to." Around 90 per cent of deaf children are born to hearing parents. This means many families are initially unfamiliar with deafness. That was the case for Liz Speilman, whose two-and-half-year-old son, Louis was diagnosed with hearing loss shortly after birth. "We didn't know anything about hearing loss. We don't have anyone that's deaf in our family. So it was a new world to us as well." Louis, who has been fitted with a cochlear implant, has been taking part in therapy sessions at Shepherd Centre every week for the past two years. "It's incredible. I'm still blown away. At his two-year speech assessment, he was categorised as in the advance section for kids of his age. So that's not just deaf kids, it's kids with typical hearing as well. So he's not just doing well, he's flying."
The Australian
12 hours ago
- The Australian
Spike in adverse event reports for ADHD medication Vyvanse
Authorities are investigating a spike in incidents involving one of Australia's most widely used ADHD medications. Adverse event reports linked to medication Vyvanse have spiked massively this year, and the manufacturer says no changes in the chemical production have been made. 'The Therapeutic Goods Administration (TGA) is currently investigating a potential safety signal associated with Vyvanse, including independent testing of the medicine through the TGA Laboratories,' a spokesperson told NewsWire. 'The investigation is the result of a recent increase in adverse event notifications relating to concerns about the quality, safety, and reduced effectiveness of the drug.' The TGA issued an alert about a typo on the Vyvanse label earlier this year. Picture: TGA 'There are no compliance signals currently under investigation for the facilities used in the manufacture of this product.' A 'signal' is detection of a pattern which requires further investigation. While not formally a pattern in the TGA's eyes, reports of adverse events such as anxiety, ineffectiveness and insomnia have increased massively this year. There have also been 88 reports of issues with the medicines label, which was flagged by the TGA earlier this year for minor typos; however, one of the typos added an extra 'S' to the word capsule; 'Each capsules contains 60mg lisdexamfetamine dimesilate'. The TGA maintains the Database of Adverse Event Notifications, where people report issues with medications. There have been 320 adverse events linked to Vyvanse in the first half of this year, compared to nine reports in the second half of 2024. Inclusion in the database does not confirm the incident is caused by the medication. Reports of ineffective Vyvanse have hit 150 so far this year, along with 88 reports of anxiety, and 73 reports that the therapeutic response has decreased. Last year, 1.8m Vyvanse prescriptions were written in Australia, excluding Department of Veterans' Affairs patients, over-the-counter drugs, private prescriptions and public inpatient prescriptions. Picture: NewsWire / Martin Ollman Prescriptions of Vyvanse have been steadily increasing for the past few years. More than 958,000 scripts were written by public system health workers in 2022, rising to 1.4 million in 2023, and then 1.8m last year, government data shows. In a statement, supplier Takeda Pharmaceuticals Australia said a change of manufacturing facility in 2024 did not alter the chemical composition of the medicine. 'There have been no changes to the formulation,' a Takeda spokesperson told the ABC. Vyvanse was produced with strict quality controls, in line with Australia's Therapeutics Goods Act, the spokesperson said. The labelling typo did not affect the quality of the medication, they said. Blair Jackson Reporter Blair's journalism career has taken him from Perth, to New Zealand, Queensland and now Melbourne. Blair Jackson
News.com.au
16 hours ago
- News.com.au
Spike in ADHD medication adverse event reports
Authorities are investigating a spike in incidents involving one of Australia's most widely used ADHD medications. Adverse event reports linked to medication Vyvanse have spiked massively this year, and the manufacturer says no changes in the chemical production have been made. 'The Therapeutic Goods Administration (TGA) is currently investigating a potential safety signal associated with Vyvanse, including independent testing of the medicine through the TGA Laboratories,' a spokesperson told NewsWire. 'The investigation is the result of a recent increase in adverse event notifications relating to concerns about the quality, safety, and reduced effectiveness of the drug.' 'There are no compliance signals currently under investigation for the facilities used in the manufacture of this product.' A 'signal' is detection of a pattern which requires further investigation. While not formally a pattern in the TGA's eyes, reports of adverse events such as anxiety, ineffectiveness and insomnia have increased massively this year. There have also been 88 reports of issues with the medicines label, which was flagged by the TGA earlier this year for minor typos; however, one of the typos added an extra 'S' to the word capsule; 'Each capsules contains 60mg lisdexamfetamine dimesilate'. The TGA maintains the Database of Adverse Event Notifications, where people report issues with medications. There have been 320 adverse events linked to Vyvanse in the first half of this year, compared to nine reports in the second half of 2024. Inclusion in the database does not confirm the incident is caused by the medication. Reports of ineffective Vyvanse have hit 150 so far this year, along with 88 reports of anxiety, and 73 reports that the therapeutic response has decreased. Prescriptions of Vyvanse have been steadily increasing for the past few years. More than 958,000 scripts were written by public system health workers in 2022, rising to 1.4 million in 2023, and then 1.8m last year, government data shows. In a statement, supplier Takeda Pharmaceuticals Australia said a change of manufacturing facility in 2024 did not alter the chemical composition of the medicine. 'There have been no changes to the formulation,' a Takeda spokesperson told the ABC. Vyvanse was produced with strict quality controls, in line with Australia's Therapeutics Goods Act, the spokesperson said. The labelling typo did not affect the quality of the medication, they said.
